Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy
| Autor: | Ana da Silva Filipe, David F. Bibby, Elihu Aranday-Cortes, Emma Hudson, Jennifer Benselin, Phil Troke, Carmen F. Manso, Brendan Healy, Daniel Bradshaw, Anthony Brown, David A. Smith, Joshua B Singer, John McLauchlan, William L. Irving, Eleanor Barnes, Jean L. Mbisa, M. Azim Ansari, E. Thomson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Carcinoma Hepatocellular Cirrhosis Genotype Sustained Virologic Response Sofosbuvir Voxilaprevir Hepatitis C virus education Hepacivirus medicine.disease_cause Antiviral Agents Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Virology medicine Humans 030212 general & internal medicine Univariate analysis Hepatology business.industry Liver Neoplasms Hepatitis C Chronic medicine.disease Hepatitis C digestive system diseases humanities Infectious Diseases Hepatocellular carcinoma Retreatment Cohort Drug Therapy Combination 030211 gastroenterology & hepatology business medicine.drug |
| ISSN: | 1352-0504 1365-2893 |
| Popis: | Sustained viral response (SVR) rates for direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is a potent DAA combination primarily used for the retreatment of patients who failed by DAA therapies. Here we evaluate retreatment outcomes and the effects of resistance-associated substitutions (RAS) in a real-world cohort, including a large number of genotype (GT)3 infected patients. 144 patients from the UK were retreated with SOF/VEL/VOX following virologic failure with first-line DAA treatment regimens. Full-length HCV genome sequencing was performed prior to retreatment with SOF/VEL/VOX. HCV subtypes were assigned and RAS relevant to each genotype were identified. GT1a and GT3a each made up 38% (GT1a n = 55, GT3a n = 54) of the cohort. 40% (n = 58) of patients had liver cirrhosis of whom 7% (n = 4) were decompensated, 10% (n = 14) had hepatocellular carcinoma (HCC) and 8% (n = 12) had received a liver transplant prior to retreatment. The overall retreatment SVR12 rate was 90% (129/144). On univariate analysis, GT3 infection (50/62; SVR = 81%, p = .009), cirrhosis (47/58; SVR = 81%, p = .01) and prior treatment with SOF/VEL (12/17; SVR = 71%, p = .02) or SOF+DCV (14/19; SVR = 74%, p = .012) were significantly associated with retreatment failure, but existence of pre-retreatment RAS was not when viral genotype was taken into account. Retreatment with SOF/VEL/VOX is very successful for non-GT3-infected patients. However, for GT3-infected patients, particularly those with cirrhosis and failed by initial SOF/VEL treatment, SVR rates were significantly lower and alternative retreatment regimens should be considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text